ClinicalTrials.gg
RecruitingNCT04731155PERFECT-AMIUpdated May 21, 2025

Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction

A Phase 4 interventional study of PCSK9 inhibitor (Alirocumab)plus standard medications and standard medications in Early PCSK9 Inhibitor on Ventricular Remodling, sponsored by Shanghai Tong Ren Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by Shanghai Tong Ren Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Apr 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary percutaneous intervention(PPCI). Totally,twenty acute myocardium infarction subjects will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy for AMI including PPCI. The experiment group will receive first PCSK9 inhibitor before PPCI, then twice a month until 3 months later. Six month after AMI, Myocardial salvage index will be used to evaluate ventricular remodeling. TnI peaking time and LDL control rates also will be recorded and compared.

02

Conditions studied

  • Early PCSK9 Inhibitor on Ventricular Remodling
03

In context

Lead sponsor

Shanghai Tong Ren Hospital is the lead sponsor of 17 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be at least 18 years of age and less than 80 years old
  2. Patients should have undergone successful percutaneous coronary intervention with drug-eluting stent for AMI and LAD should be the only culprit vessel.
  3. Subject understand the study requirements and the treatment procedures and provided before the procedure

Exclusion criteria

Exclusion Criteria:

  1. Female of , unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
  2. Known or to study medications
  3. Plan to receive revascularization in next six month.
  4. Have received revascularization before.
  5. Subjects with life expectation less than one year.
  6. Subjects with active malignant tumor
  7. subjects with severe liver or renal dysfunction( >5倍ULA,\<15ml/min/1.73mm2)
  8. Other conditions which the investigators think not applicable to the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    standard group

    Drug: standard medications

  • Experimental
    experiment group

    Drug: PCSK9 inhibitor (Alirocumab)plus standard medications

Interventions

  • DrugPCSK9 inhibitor (Alirocumab)plus standard medications

    PCSK9 inhibitor(Alirocumab) was giving to subjects before PPCI and continued twice a month until 3 month after AMI

  • Drugstandard medications

    standard medications was giving to subjects according guidelines

06

What researchers measure

Primary outcomes

  1. myocardial salvage index measured by MRI

    Time frame: one week after PPCI

  2. myocardial salvage index measured by MRI

    Time frame: six months after PPCI

  3. eject fraction measured by MRI

    Time frame: one week after PPCI

  4. eject fraction measured by MRI

    Time frame: six month after PPCI

Secondary outcomes

  1. the change of serum level of TnI/T

    Time frame: 0,6 ,12,18 , 24 ,30,and 36 hours after PPCI

  2. LDL -C control rate

    Time frame: the first month after PPCI

  3. the serum lever of hsCRP

    Time frame: Baseline (before PPCI)

  4. the serum lever of hsCRP

    Time frame: one week after PPCI

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2021 (actual). Primary completion is estimated for Oct 2025, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2021
First posted
Jan 29, 2021
StartActual
Apr 12, 2021
Primary completionEst.
Oct 2025
CompletionEst.
Oct 2025
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04731155
Lead sponsor
Shanghai Tong Ren Hospital
Responsible party
Hou Lei (Principal Investigator, Shanghai Tong Ren Hospital) — Principal investigator
First posted
Jan 29, 2021
Start date
Apr 12, 2021
Primary completion
Oct 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
May 21, 2025

Study contacts

Lei Hou, Doctor
Contact
Dr_houlei@163.com
13564868096

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion